(Q35206370)

7 August 2017

1 reference

title

Incorporating monoclonal antibodies in blood and marrow transplantation (English)

1 reference

7 August 2017

1 reference

Sami N Malek

1

1 reference

7 August 2017

Ian W Flinn

series ordinal

2

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

30

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

520-530

1 reference

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Improving outcomes in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900238-0

7 January 2021

10.1016/S0093-7754(03)00238-0

Identifiers

DOI

1 reference

7 August 2017

1 reference